ID: MRFR/Pharma/1046-HCR | 90 Pages | Published By Rahul Gotadki on March 2023
The Breathing Disorders Treatment market is expected to reach USD 141097.21 Million by 2030 at 16.90% CAGR during the forecast period 2022-2030. Breathing disorders are the one that affects the lungs and other parts of respiratory system. These breathing disorders include chronic sinusitis, asthma, and chest congestion. The person suffering from breathing problems faces various symptoms such as runny nose, nasal congestion, itchy or watery eyes, cough, chest congestion, labored breathing, wheezing, and shallow breathing. The primary factors driving the growth of breathing disorder & treatment market are increasing allergic reaction that causes breathing problem, pollen grain reaction, low blood pressure, or hypertension in individuals.
According to the World Health Organization, it was estimated, that 383,000 people died due to asthma in 2015. The rising prevalence of asthma among the population is likely to boost the market growth.
However, stringent government regulation related to drug launch, side effects, and allergic reactions due to steroids may hinder the market growth during the forecasted period
The breathing disorders treatment market has been segmented into drug class, indication, and end users.
By drug class the market has been segmented into antibiotics, non-steroidal anti-inflammatory drug (NSAIDS), cough suppressant, nasal decongestant, and others.
On the basis of indication, the market has been segmented into allergic rhinitis, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), pulmonary hypertension, idiopathic pulmonary fibrosis and others.
On the basis of end user, the market has been segmented into hospital, clinics, retail pharmacies, and online pharmacies.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The breathing disorders treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European breathing disorders treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The breathing disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, Latin Korea, Australia, and the rest of Asia-Pacific. The breathing disorders treatment industry in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Breathing disorders treatment Market Share (%), by Region, 2018
Source: Centers for Disease Control and Prevention (CDC), Eurostat, White Papers, Company Presentations, Annual Reports
Geographically, the market has been segmented, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. It is estimated that Americas dominated the breathing disorders treatment market owing to the increasing prevalence of respiratory disorders, rising geriatric population and heart-related problems. According to the Centers for Disease Control and Prevention 2017, 8.9 million adults were diagnosed with chronic bronchitis in the US and 135,268 number of deaths occurred due to chronic lower respiratory diseases. Such high prevalence of respiratory diseases in the US is expected to boost the market growth in America.
Europe stood second largest in the breathing disorders treatment market owing to the increasing health problems such as hypertension, stress, obesity, and changing lifestyle among the population. The increase pollution and environmental changes are also contributing in the demand for breathing treatment. According, to the article published on NHS Digital 617,000 patients were under treatment in NHS hospitals because of obesity in 2016. The increasing obesity leads to cause breathing problems and hyperventilation to the patient, which will increase the demand for breathing treatment.
Asia-Pacific was anticipated to be the rapidly growing region for the breathing disorders treatment market. The market is expected to witness growth owing to the increasing population and rising demand for pharmaceutical products required for the treatment of asthma, chronic obstructive pulmonary disease (COPD), wheezing, and other breathing-related disorders. The prevalence of asthma is high in developing countries and cities, such as Japan, Hong Kong, and Singapore which support the market growth.
The market in the Middle East and Africa holds a low share in the breathing disorders treatment market due to the presence of a low number of healthcare facilities, low per capita income and people living in underdeveloped countries are not much aware of the upcoming treatment methods. However, the market is expected to witness growth due to increasing hospitals and rising demand for the products in the Middle East.
Breathing disorders treatment Market, by Drug Type
Breathing disorders treatment Market, by Indication
Breathing disorders treatment Market, by End User
Breathing disorders treatment Market, by Region
|Market Size||2027: Significant Value|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Drug Type, Indication and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Abbott, Medtronic plc, Hoffmann-La Roche Ltd, Novartis AG, Reddy’s Laboratories, Amgen, Aurobindo Pharma., Bayer AG, Biogen|
|Key Market Opportunities||The rising prevalence of asthma among the population|
|Key Market Drivers||
Breathing disorders treatment market CAGR would be 16.90% during the forecast period.
Strict regulations, side-effects, and allergic reactions can hold back Breathing disorders treatment market.
Breathing disorders treatment market hospitals, clinics, retail pharmacies, and online pharmacies.
Breathing disorders treatment market has indications like chronic obstructive pulmonary disease (COPD), allergic rhinitis, cystic fibrosis (CF), asthma, idiopathic pulmonary fibrosis, pulmonary hypertension, and others.
The Americas would lead the breathing disorders treatment market.